Vaccine Code Set Update Publication Date: October 20, 2022
The individual filenames included in this distribution contain the publication date (20221020)
Release Notes: This release includes updates for all vaccine codes except Vaccine Information Statement (VIS) codes and maps.
Release notes are designed as a guide to highlight changes that have been made to the vaccine codes since the last publication. They should not be used as the primary source of code information. The vaccine code files themselves should be utilized.
General Note Regarding This Release: Codes with "Last Update" dates from 9/20/2022 to 10/19/2022, reflect the changes and additions in this release. This release includes the following code set updates:
- COVID-19 Related Code Updates
- Pfizer bivalent vaccine ages 6 months through 4 years – new code additions (Pre-EUA authorization)
- Moderna bivalent booster vaccine ages 6 months through 5 years – new code additions (Pre-EUA authorization)
- Novavax FDA EUA amendment authorizing booster dose of same product and dose as primary series for ages 18 years and older
- Sanofi Codes retired
- Other COVID-19 Related Code Changes
- Vaccine Code Set Updates Not Related to COVID-19
- New NDCs and mapping for PREVNAR 20
- NDCs Retired
- NDC GTIN code updates
- MVX Code Update
- Other NDC changes
Vaccine Code Set Updates
The core CDC IIS vaccine data code sets IIS Data Code Sets | CDC have been updated to reflect the changes in this release.
The COVID-19 Related Codes Tables for the US Vaccines and for the Emergency Use Authorization (EUA) Recipient/Caregiver Fact Sheets have been updated to reflect the changes in this release. These can be found at IIS COVID-19 Vaccine Related Code | CDC
1. COVID-19 Related Code Updates
Pre-EUA Authorization New Codes: Two new CVX codes have been added and mapped to new NDC codes in anticipation of potential EUA for bivalent vaccines.
- Moderna: New CVX Code has been added in anticipation of potential EUA for bivalent booster vaccine for ages 6 months through 5 years. CPT Codes not yet available. See table below.
CVX Code | CVX Description |
|---|
230 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent booster, preservative free, 10 mcg/0.2 mL dose |
|---|
FDA Status | Description | Unit of Sale | Unit of Use |
|---|
Pre-EUA authorization | 10 mcg/0.2 mL dose booster of Original and Omicron BA.4 & BA.5 COVID-19 strains | 80777-283-99 | 80777-283-02 |
|---|
- Pfizer: New CVX Code has been added in anticipation of potential EUA for bivalent vaccine for ages 6 months through 4 years. CPT Codes not yet available. See table below.
CVX Code | CVX Description |
|---|
302 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 3 mcg/0.2 mL dose, tris-sucrose formulation |
|---|
FDA Status | Description | Unit of Sale | Unit of Use |
|---|
Pre- EUA authorization | 3 mcg/0.2 mL dose
Original and Omicron BA.4 & BA.5 COVID-19 strains | 59267-0609-2 | 59267-0609-1 |
|---|
New FDA Authorization: Novavax. On 10/19/2022 FDA Authorized booster doses for ages 18 years and older. The newly authorized booster dose is of the same dose strength and volume as the EUA authorized primary series doses from the same NDCs. AMA has added a new CPT Administration dose code. All CDC vaccine codes remain the same as shown in the table below. A separate VIS Code Set update and release notes will be published for the new EUA Fact Sheet edition.
CVX Code | CVX Description |
|---|
211 | SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL dose |
|---|
FDA Status | Description | Unit of Sale | Unit of Use |
|---|
EUA Authorized | 5 mcg/0.5 mL, primary series ages 12 years and older, booster ages 18 years and older | 80631-100-10 | 80631-100-01 |
|---|
Pre-EUA Manufacturer Submission Withdrawn: Sanofi. Manufacturer has advised CDC that it will not be pursuing authorization of a vaccine under EUA at this time.
Sanofi pre-EUA authorization codes have been retired as follows:
CVX Codes | CVX Code Changes |
|---|
225, 226 | CVX Status set to "Never Active" |
|---|
Unit of Sale | Unit of Use | NDC Code Changes |
|---|
80631-100-10 | 80631-100-01 | NDC End Dates set to 10/31/2022 |
|---|
Other COVID-19 CVX Code Changes:
The Note fields in the following CVX codes have been updated to reflect recent EUA status updates and other details for the following CVX codes. No other changes made to these CVX codes.
- Pfizer CVX codes 300 and 301
- Moderna CVX code 229
2. Vaccine Code Updates Not Related to COVID-19
New NDCs for PREVNAR 20 added and mapped to existing CVX and MVX codes
Sale Proprietary Name | Sale Labeler | Unit of Sale NDC11 | Unit of Use NDC11 | CVX Code | CVX Description | MVX Code |
|---|
PREVNAR 20 | A-S Medication Solutions | 50090-6026-00 | 50090-6026-01 | 216 | Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF | PFR |
|---|
- Retired NDCs: The following NDC codes have been retired in this code set release.
Sale Proprietary Name | Sale Labeler | Unit of Sale NDC11 | Unit of Use NDC11 |
|---|
ZOSTAVAX | Merck Sharp & Dohme LLC | 0006-4963-00 | 0006-4963-01 |
|---|
ZOSTAVAX | Merck Sharp & Dohme LLC | 0006-4963-41 | 0006-4963-01 |
|---|
- Other Vaccine Code Additions and Changes
- MVX Code PSC (Protein Sciences) has been reactivated. It is a subsidiary of Sanofi. At this time there are no active vaccine NDCs mapped to PSC.
- GTIN Codes have been added to NDCs for products with confirmed 2D barcoding on the carton or vial. The GTIN updates were applied to 13 Units of Use and 19 Units of Sale.
- FDA files received and processed by the CDC included minor changes to a number of NDCs. These changes did not impact CDC codes. However, the updates did change the date of last update on the records.
